IRIS
FORCONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.592
EU - Europa 6.975
AS - Asia 4.475
SA - Sud America 1.068
AF - Africa 290
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 10
Totale 26.422
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.484
GB - Regno Unito 1.696
CN - Cina 1.682
RU - Federazione Russa 1.313
SG - Singapore 1.228
IE - Irlanda 1.027
BR - Brasile 868
UA - Ucraina 832
FR - Francia 525
SE - Svezia 447
HK - Hong Kong 440
VN - Vietnam 429
IT - Italia 372
DE - Germania 351
KR - Corea 267
FI - Finlandia 222
ZA - Sudafrica 188
IN - India 85
AR - Argentina 60
BD - Bangladesh 52
CA - Canada 45
EC - Ecuador 41
IQ - Iraq 39
MX - Messico 38
TR - Turchia 38
NL - Olanda 29
PK - Pakistan 29
NG - Nigeria 28
ID - Indonesia 26
AT - Austria 23
VE - Venezuela 23
PL - Polonia 22
JP - Giappone 21
UZ - Uzbekistan 21
CO - Colombia 19
ES - Italia 19
PY - Paraguay 17
SA - Arabia Saudita 17
MA - Marocco 16
CL - Cile 15
BE - Belgio 14
AU - Australia 12
CZ - Repubblica Ceca 11
IL - Israele 11
KE - Kenya 11
EU - Europa 10
LT - Lituania 10
PH - Filippine 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
HR - Croazia 9
JO - Giordania 9
TN - Tunisia 9
UY - Uruguay 9
GR - Grecia 8
PE - Perù 8
AZ - Azerbaigian 7
DZ - Algeria 7
MY - Malesia 7
AL - Albania 6
BO - Bolivia 6
CI - Costa d'Avorio 5
ET - Etiopia 5
JM - Giamaica 5
OM - Oman 5
TH - Thailandia 5
BA - Bosnia-Erzegovina 4
IR - Iran 4
KG - Kirghizistan 4
LU - Lussemburgo 4
NP - Nepal 4
PA - Panama 4
PS - Palestinian Territory 4
PT - Portogallo 4
RO - Romania 4
SN - Senegal 4
TT - Trinidad e Tobago 4
CH - Svizzera 3
KZ - Kazakistan 3
LV - Lettonia 3
MD - Moldavia 3
SY - Repubblica araba siriana 3
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
HN - Honduras 2
KH - Cambogia 2
MK - Macedonia 2
MM - Myanmar 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AI - Anguilla 1
Totale 26.405
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Southend 1.488
Dallas 1.131
Ashburn 1.120
Dublin 1.023
Woodbridge 1.013
Seattle 898
Houston 784
Wilmington 763
Cambridge 732
Jacksonville 667
Singapore 663
Chandler 566
Santa Clara 524
Hong Kong 433
Moscow 410
Ann Arbor 378
Beijing 358
Hefei 293
Seoul 264
Princeton 226
Nanjing 215
Siena 204
The Dalles 185
Johannesburg 169
San Jose 162
Ho Chi Minh City 146
Lauterbourg 125
Council Bluffs 100
Los Angeles 96
Hanoi 93
San Diego 88
Boardman 81
Nanchang 81
São Paulo 75
Helsinki 73
Buffalo 65
Shenyang 61
Columbus 55
Redondo Beach 45
London 44
New York 43
San Mateo 42
Hebei 40
Rio de Janeiro 37
Changsha 36
Milan 36
Shanghai 34
Norwalk 32
Jiaxing 31
Dong Ket 29
Orem 29
Tianjin 29
Da Nang 28
Frankfurt am Main 28
Abuja 27
Kunming 27
Flanders 25
San Francisco 25
Chicago 24
Bengaluru 23
Falls Church 23
Menlo Park 23
Brasília 22
Düsseldorf 22
Ningbo 22
Toronto 21
Zhengzhou 21
Belo Horizonte 20
Nuremberg 20
Tashkent 20
Hangzhou 18
Jinan 18
Curitiba 17
Guayaquil 17
Tokyo 17
Guangzhou 16
Haiphong 16
Munich 16
Warsaw 16
Brooklyn 15
Brussels 14
Baghdad 13
Cape Town 12
Dhaka 12
Goiânia 12
Mexico City 12
Porto Alegre 12
Quito 12
Washington 12
Lappeenranta 11
Montreal 11
Phoenix 11
Taizhou 11
Campinas 10
Guarulhos 10
Amsterdam 9
Atlanta 9
Fremont 9
Haikou 9
Totale 19.325
Salva come PNG Salva come JPEG
Nome #
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 297
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 287
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 286
BRAF mutations in hairy-cell leukemia 275
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 270
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 248
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 246
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 240
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 240
Alternative methods of cladribine administration 235
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 235
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 234
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells 232
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 229
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia 228
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 226
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 223
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 222
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation 222
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 221
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis 220
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 216
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 216
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 214
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 214
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 213
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma 213
Emerging drugs in chronic myelogenous leukaemia 212
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 212
The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL 211
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 211
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 211
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 210
Towards the pharmacotherapy of hairy cell leukaemia 205
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 205
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort 204
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia 204
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 204
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia 203
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 202
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 201
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 201
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 201
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 200
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia 199
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 199
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 199
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 199
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 198
Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing 198
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 197
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK 196
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 196
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 196
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array 195
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 195
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 194
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 193
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 193
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 193
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 193
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis 192
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3 190
Predicting the clinical course of Hodgkin lymphoma 189
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism 187
Bcr-abl peptides for chronic myeloid leukemia. 186
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation 186
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 185
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 185
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 183
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 181
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses 179
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 179
Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes 178
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 176
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 174
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 174
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia 173
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 173
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 171
IL-4 enhances expression and function of surface IgM in CLL cells 171
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 169
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome 168
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 168
The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia 167
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 167
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 165
Hairy cell leukaemia: biological and clinical overview from immunogenetic insights 165
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition 164
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity 164
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study 164
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 164
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 163
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 162
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy 162
Three years of ibrutinib in CLL 162
Immunogenetics features and genomic lesions in splenic marginal zone lymphoma 161
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas 161
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. 160
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function 160
Totale 19.960
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.489
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.489
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021642 0 0 0 0 0 0 0 0 0 259 222 161
2021/20221.587 110 263 52 98 71 55 86 50 89 197 168 348
2022/20232.105 158 119 312 291 224 447 34 160 243 24 59 34
2023/20241.314 68 35 68 121 33 380 457 6 7 16 9 114
2024/20253.377 91 175 222 158 461 205 73 211 276 151 316 1.038
2025/20266.505 636 1.280 880 833 1.045 305 658 327 265 276 0 0
Totale 26.574